BIOMAT Database Logo BIOMAT Database Logo

Marked thrombocytosis after CMF chemotherapy. 1989

U Bolzern, and R Biasioli, and E Rinaldi, and S Negretti

UI MeSH Term Description Entries
D008727 Methotrexate An antineoplastic antimetabolite with immunosuppressant properties. It is an inhibitor of TETRAHYDROFOLATE DEHYDROGENASE and prevents the formation of tetrahydrofolate, necessary for synthesis of thymidylate, an essential component of DNA. Amethopterin,Methotrexate Hydrate,Methotrexate Sodium,Methotrexate, (D)-Isomer,Methotrexate, (DL)-Isomer,Methotrexate, Dicesium Salt,Methotrexate, Disodium Salt,Methotrexate, Sodium Salt,Mexate,Dicesium Salt Methotrexate,Hydrate, Methotrexate,Sodium, Methotrexate
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D002945 Cisplatin An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle. Platinum Diamminodichloride,cis-Diamminedichloroplatinum(II),cis-Dichlorodiammineplatinum(II),Biocisplatinum,Dichlorodiammineplatinum,NSC-119875,Platidiam,Platino,Platinol,cis-Diamminedichloroplatinum,cis-Platinum,Diamminodichloride, Platinum,cis Diamminedichloroplatinum,cis Platinum
D005260 Female Females
D005472 Fluorouracil A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid. 5-FU,5-FU Lederle,5-FU Medac,5-Fluorouracil,5-Fluorouracil-Biosyn,5-HU Hexal,5FU,Adrucil,Carac,Efudex,Efudix,Fluoro-Uracile ICN,Fluoroplex,Fluorouracil Mononitrate,Fluorouracil Monopotassium Salt,Fluorouracil Monosodium Salt,Fluorouracil Potassium Salt,Fluorouracil-GRY,Fluorouracile Dakota,Fluorouracilo Ferrer Far,Fluoruracil,Fluracedyl,Flurodex,Haemato-FU,Neofluor,Onkofluor,Ribofluor,5 FU Lederle,5 FU Medac,5 Fluorouracil,5 Fluorouracil Biosyn,5 HU Hexal,Dakota, Fluorouracile,Fluoro Uracile ICN,Fluorouracil GRY,Haemato FU
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000971 Antineoplastic Combined Chemotherapy Protocols The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form. Anticancer Drug Combinations,Antineoplastic Agents, Combined,Antineoplastic Chemotherapy Protocols,Antineoplastic Drug Combinations,Cancer Chemotherapy Protocols,Chemotherapy Protocols, Antineoplastic,Drug Combinations, Antineoplastic,Antineoplastic Combined Chemotherapy Regimens,Combined Antineoplastic Agents,Agent, Combined Antineoplastic,Agents, Combined Antineoplastic,Anticancer Drug Combination,Antineoplastic Agent, Combined,Antineoplastic Chemotherapy Protocol,Antineoplastic Drug Combination,Cancer Chemotherapy Protocol,Chemotherapy Protocol, Antineoplastic,Chemotherapy Protocol, Cancer,Chemotherapy Protocols, Cancer,Combinations, Antineoplastic Drug,Combined Antineoplastic Agent,Drug Combination, Anticancer,Drug Combination, Antineoplastic,Drug Combinations, Anticancer,Protocol, Antineoplastic Chemotherapy,Protocol, Cancer Chemotherapy,Protocols, Antineoplastic Chemotherapy,Protocols, Cancer Chemotherapy
D013922 Thrombocytosis Increased numbers of platelets in the peripheral blood. (Dorland, 27th ed) Thrombocythemia,Thrombocythemias,Thrombocytoses

Related Publications

U Bolzern, and R Biasioli, and E Rinaldi, and S Negretti
Epirubicin chemotherapy and advanced breast cancer after adjuvant CMF chemotherapy.
January 1995, Clinical oncology (Royal College of Radiologists (Great Britain)),
U Bolzern, and R Biasioli, and E Rinaldi, and S Negretti
Therapeutic thrombocytapheresis for extreme thrombocytosis after chemotherapy in essential thrombocytosis.
August 2019, Journal of clinical apheresis,
U Bolzern, and R Biasioli, and E Rinaldi, and S Negretti
[Chronic myelogenous leukemia with marked thrombocytosis].
March 2001, [Rinsho ketsueki] The Japanese journal of clinical hematology,
U Bolzern, and R Biasioli, and E Rinaldi, and S Negretti
Chronic myeloid leukaemia with marked thrombocytosis.
February 2021, EJHaem,
U Bolzern, and R Biasioli, and E Rinaldi, and S Negretti
Salvage treatment of patients suffering relapse after adjuvant CMF chemotherapy.
October 1986, Cancer,
U Bolzern, and R Biasioli, and E Rinaldi, and S Negretti
Acute lymphoblastic leukaemia after radiotherapy and adjuvant chemotherapy (CMF) for breast cancer.
January 1981, Acta haematologica,
U Bolzern, and R Biasioli, and E Rinaldi, and S Negretti
[Platelet aggregation during adjuvant chemotherapy with CMF].
June 1991, Minerva medica,
U Bolzern, and R Biasioli, and E Rinaldi, and S Negretti
Marked thrombocytosis in a child with advanced myelodysplastic syndrome.
April 2004, Leukemia & lymphoma,
U Bolzern, and R Biasioli, and E Rinaldi, and S Negretti
Marked thrombocytosis during treatment with ceftazidime for pulmonary infection.
January 2008, Pharmacy world & science : PWS,
U Bolzern, and R Biasioli, and E Rinaldi, and S Negretti
Refractory anemia with ringed sideroblasts associated with thrombocytosis: comparative analysis of marked with non-marked thrombocytosis, and relationship with JAK2 V617F mutational status.
November 2008, International journal of hematology,
Copied contents to your clipboard!